Due to a "surplus of available updated vaccines" since the pandemic, AstraZeneca announced on Tuesday that it had started the global withdrawal of its Covid-19 vaccine.
Additionally, the business said that it would remove the marketing authorizations for the vaccine Vaxzevria in Europe.
Vaxzevria, which is no longer produced or provided, is in lower demand as a result of the company`s statement that "many, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines."
According to media, opens new tab reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
The firm`s application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as Covid-19 medicine sales declined.
